Siren Biotechnology is a biotech company focused on developing innovative cancer treatments through a unique gene therapy platform. The company merges two advanced therapeutic technologies: adeno-associated virus (AAV) gene therapy and cytokine immunotherapy. This integrated approach addresses significant challenges in cancer treatment, including drug delivery, efficacy, and toxicity. By combining these methods, Siren Biotechnology aims to enhance the elimination of tumor cells and stimulate anti-tumor immune responses, offering a novel strategy for combating cancer.
Wyndly is fixing allergies. We give you lifelong allergy relief with personalized, prescription treatment and phenomenal online care. We’re making an allergy-free life easy and accessible to the 60 million Americans who suffer from environmental allergies.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, which supports advancements in synthetic biology. Situated within the prestigious Cambridge cluster of high-tech and life science organizations, Evonetix aims to revolutionize DNA synthesis through novel techniques that enhance efficiency and capability. The team at Evonetix comprises experienced professionals from various scientific and engineering disciplines, bringing together a wealth of knowledge to drive the commercialization of their technology.
Kernal Biologics, Inc. designs and develops mRNA immunotherapies. It develops mRNA immunotherapies for covid-19 and cancers. The company’s mRNA platform is used by researchers and companies working on vaccines and therapeutics for COVID-19. Kernal Biologics, Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Omada Health, Inc. is a digital healthcare company that develops online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, the company collaborates with employers and health plans to identify individuals at risk for preventable chronic conditions such as prediabetes, diabetes, hypertension, and heart disease. Omada's programs are personalized to address the evolving needs of participants, offering support in areas like diabetes prevention, type 2 diabetes management, and behavioral health. The company integrates professional health coaching, connected health devices, real-time data, and personalized feedback to achieve clinically significant outcomes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program by the Centers for Disease Control and Prevention (CDC).
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.).
The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Teiko.bio is an immune profiling platform that enables clinicians to make informed decisions around patient response. The company was founded in 2020 and is based in Salt Lake City, Utah.
OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.
Developer of a novel diagnosis technology designed to detect cancers earlier from a simple blood sample. The company's technology uses the biological features that make each cancer type and each individual person's cancer unique by focusing on the things that differentiate a cancer cell from a healthy cell, enabling healthcare professionals to conduct diagnoses of early smaller tumors and apply personalized and effective cancer treatment strategies for patients.
Ulabs Systems Inc. specializes in developing software technology for digital dental treatment planning tailored for orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers its flagship product, uLab, which allows orthodontists to create customized treatment plans based on individual patient needs. The software enables practitioners to generate aligner movement plans and print custom aligners, significantly streamlining the planning process. With its proprietary architecture and fully automated features, uLab empowers orthodontists to create chairside treatment plans in under five minutes, marking a notable advancement in orthodontic technology.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Kit specializes in at-home health testing solutions, providing comprehensive kits that enable organizations to offer a safe and convenient alternative to traditional doctor and laboratory visits. By making preventative health testing accessible across various industries, Kit facilitates reliable health monitoring for customers, ensuring ease of use and enhanced accessibility. The company aims to streamline the health testing process, allowing individuals to manage their health from the comfort of their homes while supporting organizations in delivering effective health services.
Kernal Biologics, Inc. designs and develops mRNA immunotherapies. It develops mRNA immunotherapies for covid-19 and cancers. The company’s mRNA platform is used by researchers and companies working on vaccines and therapeutics for COVID-19. Kernal Biologics, Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
R-Zero Systems, Inc. manufactures, designs, and develops hospital-grade disinfection devices for businesses. Its products include R-Zero Arc, a UV-C surface and air disinfection solution that destroys pathogens for dynamic environments. It offers its solutions for enterprises, shops, restaurants, schools and hotels. R-Zero Systems, Inc. was formerly known as Guardian UV, Inc. The company was founded in 2020 and is based in San Francisco, California.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, which supports advancements in synthetic biology. Situated within the prestigious Cambridge cluster of high-tech and life science organizations, Evonetix aims to revolutionize DNA synthesis through novel techniques that enhance efficiency and capability. The team at Evonetix comprises experienced professionals from various scientific and engineering disciplines, bringing together a wealth of knowledge to drive the commercialization of their technology.
Fluent BioSciences is a privately funded life science company focused on developing high-sensitivity molecular analytical products. Utilizing proprietary instrument-free micro-self-assembly technology, the company enables the analysis of extremely low molecular and cellular sample inputs. Its platform facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative approach provides researchers in the biotechnology sector with enhanced capabilities for single-cell analysis, broadening their access to advanced analytical techniques.
Omada Health, Inc. is a digital healthcare company that develops online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, the company collaborates with employers and health plans to identify individuals at risk for preventable chronic conditions such as prediabetes, diabetes, hypertension, and heart disease. Omada's programs are personalized to address the evolving needs of participants, offering support in areas like diabetes prevention, type 2 diabetes management, and behavioral health. The company integrates professional health coaching, connected health devices, real-time data, and personalized feedback to achieve clinically significant outcomes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program by the Centers for Disease Control and Prevention (CDC).
Gali Health, Inc. is a health technology company based in San Francisco, California, established in 2015. The company focuses on developing a mobile application named Gali, which serves as a personal health assistant designed to support individuals with chronic conditions. By leveraging collective intelligence, Gali enables users to proactively manage their health through crowdsourced personal health data and medically-validated insights. The application employs artificial intelligence to provide highly personalized support, addressing medical, lifestyle, and psychological aspects of living with chronic diseases. Gali Health aims to empower users by ensuring they do not feel isolated or powerless in managing their health, advancing consumer-driven healthcare through innovative technology and personalized health tracking.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.).
The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.
Wild Earth is a technology startup based in Berkeley, California, founded in 2017. The company focuses on developing high-protein pet foods that prioritize health, environmental sustainability, and humane sourcing compared to traditional pet food products. By leveraging scientific advancements, Wild Earth aims to reinvent pet nutrition and create cleaner, more nutritious options for pet owners and their animals.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Qulab Inc. develops systems to automate drug designing. The company was founded in 2017 and is headquartered in Los Angeles, California.
Ulabs Systems Inc. specializes in developing software technology for digital dental treatment planning tailored for orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers its flagship product, uLab, which allows orthodontists to create customized treatment plans based on individual patient needs. The software enables practitioners to generate aligner movement plans and print custom aligners, significantly streamlining the planning process. With its proprietary architecture and fully automated features, uLab empowers orthodontists to create chairside treatment plans in under five minutes, marking a notable advancement in orthodontic technology.
Curai is a virtual care company that leverages artificial intelligence to provide chat-based primary care services at reduced costs. Founded in 2017 by Neal Khosla and Xavier Amatriain, the company is headquartered in Palo Alto and aims to make high-quality, affordable primary care accessible globally. Curai's platform combines the expertise of clinicians with advanced AI technologies, facilitating a learning healthcare system that enhances the efficiency and effectiveness of care delivery. By helping patients communicate relevant information to medical professionals, Curai enables more accurate diagnoses and fosters improved patient outcomes. The service is available to individuals directly or through partnerships with enterprises.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, which supports advancements in synthetic biology. Situated within the prestigious Cambridge cluster of high-tech and life science organizations, Evonetix aims to revolutionize DNA synthesis through novel techniques that enhance efficiency and capability. The team at Evonetix comprises experienced professionals from various scientific and engineering disciplines, bringing together a wealth of knowledge to drive the commercialization of their technology.
Alveo Technologies, Inc. develops innovative diagnostic devices for infectious diseases, headquartered in Alameda, California. Established in 2014, the company offers a system called be.well, which includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This platform integrates sample preparation, genetic material amplification, and real-time detection to identify various illnesses, including Flu A/B, COVID-19, and RSV. By leveraging advances in sensing, microfluidics, and bioassays, Alveo Technologies aims to empower consumers, healthcare professionals, and treatment providers with timely and accurate diagnostic information, facilitating faster and more informed healthcare decisions.
Singular Bio's technology provides single molecule analysis of a patient's DNA, giving exquisite sensitivity for detecting many common conditions. The company's mission is to expand access to fundamental healthcare information by making advanced genetic tests available to everyone.
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.
Ulabs Systems Inc. specializes in developing software technology for digital dental treatment planning tailored for orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers its flagship product, uLab, which allows orthodontists to create customized treatment plans based on individual patient needs. The software enables practitioners to generate aligner movement plans and print custom aligners, significantly streamlining the planning process. With its proprietary architecture and fully automated features, uLab empowers orthodontists to create chairside treatment plans in under five minutes, marking a notable advancement in orthodontic technology.
Making nature accessible and affordable for a growing society.It is estimated that the world’s population will increase by more than 35% by 2050, reaching 9 billion people. Crop production will need to more than double in order to feed these people and meet the consumer needs of a developing world. With very little land remaining for agricultural expansion, they as a society need to find ways to maximize the use of their world’s resources. Plants produce a variety of rare natural products which are used in their daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals and agricultural chemicals. They strive to reduce their dependence on land- and resource-intensive practices by recreating natural processes through biotechnology.
Omada Health, Inc. is a digital healthcare company that develops online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, the company collaborates with employers and health plans to identify individuals at risk for preventable chronic conditions such as prediabetes, diabetes, hypertension, and heart disease. Omada's programs are personalized to address the evolving needs of participants, offering support in areas like diabetes prevention, type 2 diabetes management, and behavioral health. The company integrates professional health coaching, connected health devices, real-time data, and personalized feedback to achieve clinically significant outcomes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program by the Centers for Disease Control and Prevention (CDC).
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Rocket Pharmaceuticals is an emerging biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. The Company’s lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1) and Infantile Malignant Osteopetrosis. The Company is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease.
MULTERRA BIO, INC. develops a handheld device for performing various diagnostics with a single and consumable cartridge. The company was incorporated in 2015 and is based in San Francisco, California.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.